Charles Schwab Investment Management Inc. Has $21.09 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS

Key Points

• Charles Schwab Investment Management Inc. reduced its holdings in Apellis Pharmaceuticals by 3.2%, selling 32,249 shares and currently owns approximately 0.77% of the company, valued at $21.1 million.
• Insider transactions have seen significant sales including CEO Cedric Francois, who sold 19,725 shares, and General Counsel David O. Watson, who sold 5,000 shares, reflecting recent decreases in their ownership stakes.
• Analysts are mixed on Apellis Pharmaceuticals, with ratings ranging from "Strong Buy" to "Hold," while the consensus price target is $34.12, indicating potential upside from current levels.

Charles Schwab Investment Management Inc. decreased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 3.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 964,499 shares of the company's stock after selling 32,249 shares during the period. Charles Schwab Investment Management Inc. owned 0.77% of Apellis Pharmaceuticals worth $21,094,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in Apellis Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 10,130,356 shares of the company's stock valued at $221,551,000 after acquiring an additional 84,331 shares during the period. AQR Capital Management LLC increased its position in Apellis Pharmaceuticals by 127.2% in the 4th quarter. AQR Capital Management LLC now owns 1,856,442 shares of the company's stock valued at $59,239,000 after acquiring an additional 1,039,182 shares during the period. Deutsche Bank AG increased its position in Apellis Pharmaceuticals by 1.8% in the 4th quarter. Deutsche Bank AG now owns 1,778,377 shares of the company's stock valued at $56,748,000 after acquiring an additional 30,867 shares during the period. Bank of America Corp DE increased its position in Apellis Pharmaceuticals by 72.3% in the 4th quarter. Bank of America Corp DE now owns 1,680,213 shares of the company's stock valued at $53,616,000 after acquiring an additional 705,209 shares during the period. Finally, Polar Capital Holdings Plc increased its position in Apellis Pharmaceuticals by 45.8% in the 4th quarter. Polar Capital Holdings Plc now owns 1,577,175 shares of the company's stock valued at $50,328,000 after acquiring an additional 495,175 shares during the period. Institutional investors own 96.29% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on APLS. Scotiabank lowered their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Royal Bank Of Canada lifted their price target on Apellis Pharmaceuticals from $17.00 to $19.00 and gave the company a "sector perform" rating in a research report on Friday, August 1st. JPMorgan Chase & Co. lifted their price target on Apellis Pharmaceuticals from $35.00 to $37.00 and gave the company an "overweight" rating in a research report on Monday, August 4th. Cantor Fitzgerald lifted their target price on Apellis Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Finally, Wells Fargo & Company lifted their target price on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an "equal weight" rating in a report on Monday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.12.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 19,725 shares of the firm's stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $20.21, for a total value of $398,642.25. Following the completion of the sale, the chief executive officer owned 331,605 shares of the company's stock, valued at $6,701,737.05. This trade represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel David O. Watson sold 5,000 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $27.80, for a total value of $139,000.00. Following the completion of the sale, the general counsel directly owned 123,730 shares of the company's stock, valued at approximately $3,439,694. This trade represents a 3.88% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,090 shares of company stock valued at $3,542,832. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Stock Up 1.0%

Shares of Apellis Pharmaceuticals stock traded up $0.29 during midday trading on Wednesday, hitting $28.22. The company's stock had a trading volume of 2,301,812 shares, compared to its average volume of 2,806,813. The firm has a market capitalization of $3.56 billion, a P/E ratio of -15.51 and a beta of 0.78. The stock has a 50-day simple moving average of $21.56 and a 200-day simple moving average of $21.39. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. Apellis Pharmaceuticals, Inc. has a 1-year low of $16.10 and a 1-year high of $41.94.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.11. The business had revenue of $171.39 million during the quarter, compared to analysts' expectations of $187.91 million. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.Apellis Pharmaceuticals's revenue was down 10.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.30) earnings per share. As a group, sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).